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What Do We Need to Consider for 
Pain Management?
Srini Chary
Abstract
Chronic pain in palliative care is viewed as an illness but remains as a subjec-
tive symptom. Hence, we must consider genetics, pain experience, coping skills, 
epigenetic effects, mental health, social determinants of health, interventions, and 
molecular biology. Acute pain transitions to chronic pain in some individuals follow-
ing an injury, and there is poor evidence to stop such change. Acute, Chronic, and 
mixed pain can occur in patients with trauma, cancer, organ failure due to primary 
illness and other co-morbidities. The response to interventions may include biopsy-
chosocial, non-pharmacological, surgery, radiation, chemotherapy, interventional 
radiology, pharmacological and depending upon survivorship, consider what is 
appropriate with peer reviewed medical evidence. Neurobiology is important in rela-
tion to physical and psychological issues; it affects an expression of pain. Manageable 
pain and relief are considered as being Human Right. Lack of adequate knowledge 
and treatment resources are common for care providers and patients. Cancer and 
noncancer pain ought to consider collaborating with interdisciplinary palliative 
approach, palliative care, and end of life care along with acute, chronic, and mixed 
pain management. Cancer patients with survivorship is increasing and risk manage-
ment with chemicals, noncancer individuals appear similar. Barriers include health 
professional education, lack of treatment resources, medical, economic, ethical, and 
legal reasons. Pain management as an illness, care providers considers patient and 
family centered approach, useful to the community.
Keywords: pain taxonomy, genetics, epigenetic effects, biopsychosocial,  
molecular biology, interventions
1. Introduction
As a care provider, we must consider up to date pain management skills beneficial 
to individual patient. Valuing, dignity and hope along with better therapeutic relation-
ship with the patient, allows us to return home happier at the end of the day. Relief 
of pain is not effective; health care professionals feel uncomfortable and complain 
around the world.
In 1967, the world’s first purpose-built, St Christopher’s Hospice in south 
London, England by Dame Cicely Saunders, who was a nurse, social worker 
and became a physician for “end of life care and clinical research” in the United 
Kingdom. Dr. Robert Twycross and from Canada Dr. Balfour Mount had worked 
with Dame Cicely Saunders and Dr. Mount came up with a term “Palliative Care” in 
1973 which within a short time, the entire world accepted.
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World Health Organization (WHO) present definition comprises: “Palliative 
care is an approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the prevention 
and relief of suffering by means of early identification and impeccable assessment 
and treatment of pain and other problems, physical, psychosocial and spiritual.”
More recently “Palliative Approach, Palliative Care and End of Life Care” has 
been accepted internationally as well as also “Early, Integrated, Collaborative and 
Inter-professional Care”. Advanced care planning, goals of care, and good com-
munication with relevant language and words reduce distress of patient and family 
(Figure 1).
Now palliative care has patients with palliative approach, palliative care, end of 
life care and survivorship with cancer or organ failure. Dr. Pippa Hawley explained 
the value of a visual “Bow Tie Model” as a disease management and palliative care 
triangles can be adopted for cancer and non-cancer interventions [1].
At the end of last century, pain management and scientific research had 
improved but chronic pain and palliative care specialists with present knowledge 
were limited in Canada and other parts of the world.
The Gold Standards Framework from the UK has prognostic indicators; general, 
cancer, and organ failure trajectories, which are important and useful to consider, 
before treatment plan [2].
In 2007, Boulanger et al., did a study whether chronic non-cancer pain has 
improved, though more patients were receiving medical analgesics, the changes 
were minor and could be better in Canada [3].
Genetics play a major role with physical, psychological health or illness and 
our knowledge and management is improving [4, 5]. Nutrition has a role in pain 
management and requires learning care providers, patients, and families [6].
Optimal pain management requires history, physical examination, investiga-
tions, and appropriate interventions. In the past four to five years “opioid crisis” 
increased deaths due to the use of illicit fentanyl [7]. “Pain crisis” is an experience of 
a patient relating to pain and requires immediate interventions, whereas “opioid cri-
sis” relates to substance use disorder or an error with medication or illicit drug use.
IASP, pain and palliative care societies across the world are encouraging physi-
cians and interprofessional team members to consider interventions for pain 
management, clinical research and in the past three decades, several peer reviewed 
manuscripts have been published for pain management with such evidence and 
knowledge, can reduce pain in an individual and community can prosper.
Figure 1. 
Bow Tie Model: Bow Tie Model: Palliative care is an interdisciplinary coordination at the time of diagnosis and 
the timelines can vary in an individual head towards survivorship with cure or illness is controlled and requires 
supportive care or some individuals can be at the end of life.
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2. Optimal pain management
International Association for the study of pain (IASP) has revised, 1979 defini-
tion of pain in 2020 considering concepts, challenges and compromises and stated 
“An unpleasant sensory and emotional experience associated with, or resembling 
that associated with, actual or potential tissue damage” and is relevant for pain 
management [8].
Pain perception and expression is associated with molecular biology which 
includes transmission of signals from an injury, transmitting through spinothalamic 
tract to thalamus in the brain, in nanoseconds, the signals move to limbic system. 
Alteration in the limbic system, changes in neurotransmitters, tissue receptors lead 
to high expression of pain, anxiety, frustration, and major depression.
2.1 Acute pain
Acute pain like “stubbed toe or a needlestick” disappears in a few minutes 
secondary to the antinociceptive nervous system triggered and the pain stimuli 
release endorphins within the brain, and enkephalins in the brain stem, which 
block the transmission of pain signals at different levels and the ion channels are 
functioning.
However, the acute pain secondary to cell injury caused by pressure, heat, 
chemicals, or physical stimulus; damaged cells release lysosomes which causes 
inflammation within hours and magnifies the pain signals through the release of 
signaling chemicals such as prostaglandins, arachidonic acid and leukotrienes in the 
nervous system and involves glutamate at low levels. Ion channels may not function 
appropriately thus endorphins may not be active [9].
Acute nerve injury associated with acute neuropathic pain, e.g., broken bone, 
amputation.
2.2 Chronic pain
Acute, nociceptive, and inflammatory pain can transition to chronic pain, if 
the pain persists more than 3 months in an individual. In this period of transi-
tion, the ion channel function may not be normal, and endorphins may not be 
active.
Following an acute injury; infection, crush or nerve injury, degeneration of 
tissues, micro, macro vascular insufficiency, and cancer the recovery is low, and 
healing is slower, leading to chronic pain associated with poor quality of life.
Palliative and end of life care, some patients who are dependent, frail and 
require extensive nursing care may have pain crisis along with delirium. Identifying 
the difference between the symptoms, pain and delirium, using appropriate phar-
macological interventions are useful. Refractory symptoms like delirium, respira-
tory distress, seizures may need palliative sedation. Patients with pain and agitation 
may require analgesic and intermittent or palliative sedation [10].
2.3 Cancer and pain
Advanced cancer trajectory leads to end of life, pain crisis or delirium and other 
co-morbidities need to be considered. However, if patient responds to intervention, 
almost 50% of them are in survivorship and not end of life, requiring long-term 
pain and symptom management. Cancer pain is often a “mixed pain” as inflamma-
tion around primary or metastasis is common [11].
Pain Management
4
2.4 Tissue injury, organ failure, comorbidities, and pain
Soft tissue or bone in the elderly have more issues like arthritis, tissue injury and 
healing can be poor giving rise to the pain. Acute or Chronic kidney disease (AKI or 
CKD) with comorbidities require pain management and most opioids are excreted 
through kidney and opioid toxicity is common. Diabetes is associated with neu-
ropathy, likely microvascular insufficiency [12] (Figure 2).
2.5 Taxonomy
Nociceptive pain, neuropathic pain and nociplastic pain have been approved 
by IASP in 2019 and International Classification of Diseases (ICD-11), which the 
Figure 3. 
Taxonomy change in 2019, IASP added “Nociplastic Pain” relating to neuroplasticity and future application of 
research.
Figure 2. 
Pain classification: acute, chronic, and acute on chronic pain.
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World Health Organization adopted in the same year. These combined efforts have 
potential benefits for both research and patient care [13] (Figure 3).
Neuroplasticity is the change in neuronal pathways and synapses that occurs 
due to certain factors: behavior, environment, and neural process. Chronic pain has 
been related to central excitation, wind-up theory and IASP approved Neuroplastic 
pain; as the brain learning or neuroplasticity and alteration in the function of 
anatomy for future research an appropriate term [14, 15].
Epigenetic effects, including major depression in an individual related to 
negative experience associated with poor coping and neuroplasticity secondary to 
changes in gene–environment, psychosocial environment leading to lower levels 
of neurotrophic factors altering structural and functional aspects of brain. Such 
epigenetic effects can be generational [16–17].
3. Principles of pain management
Pain management should include biopsychosocial assessment, pain severity, 
pain descriptors and planning physical, psychological, spiritual rehabilitation, inva-
sive therapies, and pharmacological interventions for patients with acute, chronic, 
neuropathic and nociplastic pain. Patients in pain crisis and agitated often require 
pharmacotherapy initially to manage pain and following that nonpharmacological 
interventions have a value and can reduce or stop medications.
Acute pain may require anti-inflammatory medications, steroids and opioids, 
depending upon the extent of injury for a short period, which could be hours to 
days, which needs to be explained to the patient and family.
Chronic pain is associated with goal setting. If patient’s opioid use disorder risk 
is high by using “opioid Risk Tool” questionnaire, before opioids are being used 
requires boundary setting, along with written patient agreement document, for 
opioid therapy [18].
Patients with life expectancy few hours, days or weeks may need more phar-
macological interventions, as other interventions non-pharmacological to improve 
symptoms, may need longer time to respond (Figure 4).
3.1 Education
Individuals with chronic pain, and suffering may benefit with explanation of 
their pain, which is a subjective symptom along with interventional plan which 
should include in such education. Such education either individual, or group educa-
tion, depending upon the choice of the patient. Education can be verbal, written or 
online [19].
Figure 4. 
Pain management includes variety of approaches, which require to improve patient’s suffering.
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3.2 Physical medicine approach
Somatic, myofascial nociceptive pain can respond to exercise, passive physi-
cal modalities (TENS, laser, ultrasound, and massage) along with stretching has 
value in chronic back, neck and shoulder pain. Elderly, chronic pain, neuropathic, 
psychosocial and cancer pain patients/individuals may require interprofessional 
management [20, 21].
3.3 Psychosocial approach
Chronic pain in some patients is associated with alteration in the function and 
anatomy of limbic system in the brain and prefrontal system is not comfortable.
Cognitive-behavioral therapy (CBT) for chronic pain management has been 
used widely. Dennis Turk first described in 1983 education, skill acquisition, cogni-
tive and behavioral rehearsal, generalization, and maintenance, and in review 2008 
CBT, self-management skills and other suggestions [22].
Vulnerable populations with pain require social and financial rehabilitation 
along with multidisciplinary engagement.
3.4 Spiritual approach
Spiritual awakening as non-medical approach: meditation seems to benefit 
self-management skills, emotional improvement, and empowerment. Physical pain 
and discomfort in an individual may improve, whether neurotransmitters alter to 
benefit emotions.
3.5 Interventional approaches
3.5.1 Surgery
For patients with a reversible pain diagnosis due to fracture, obstruction, per-
foration and other causes, surgical intervention is possible and beneficial. Chronic 
pain improves with deep brain or spinal stimulation, which requires surgery [23].
3.5.2 Radiation therapy
Primary cancer and metastasis either curative or palliative- the intention is to 
reduce acute or chronic pain. It is a local therapy and initial fractions may increase 
pain due to inflammation. Systemic injection of radionuclide was used few decades 
ago for bone metastasis, but at present it is used for thyroid cancer as a primary 
therapy only [24].
3.5.3 Chemo and immune therapy
Patients with cancer pain receiving chemotherapy, initially the pain may increase 
due to necrotic tumor and inflammation. After two or three cycles of chemotherapy 
the tumor may reduce in size and pain may improve along with other symptoms.
3.5.4 Interventional radiology (IR)
Lately nerve mapping is better and anatomically using local anesthetic, steroids 
or other medications can reduce or stop pain for a few weeks. IR can be used for 
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palliative bone/musculoskeletal and neuropathic pain in the form of cryoabla-
tion, microwave thermal ablation, plasma medicated radiofrequency ablation. 
Vertebroplasty and kyphoplasty along with stent therapy is possible [25].
Sympathetic blockade, stellate ganglion, coeliac and splanchnic plexus, and 
lumbar plexus block is possible to reduce sympathetically medicated pain and 
symptoms.
3.5.5 Neuraxial therapy
Palliative and end of life care when the pain is not manageable epidural and 
spinal analgesia using local anesthetic, opioid, alpha-2 agonist, and other pharma-
ceuticals to control pain is available [26].
3.5.6 Pharmacological
Non-opioid analgesics such as anti-inflammatory; acetaminophen, NSAIDs and 
Cox-2 inhibitors are used for acute pain but less effective with chronic pain including 
neuropathic or nociplastic pain. Such medications are associated with adverse effects 
and a therapeutic trial is useful in an individual and testing appropriate dose is useful 
and not harmful.
3.6 Adjuvants, co-analgesics: systemic and topical
Antidepressants and anticonvulsants have been used as systemic adjuvants for 
chronic pain and neuropathic pain. Number needed to treat (NNT) and number 
needed to harm (NNH) was adapted from Finnerup et al. in 2005 and 2007. Topical 
adjuvants include lidocaine patch and capsaicin and ointment and topical formulation 
with certain local anesthetic, amitriptyline, ketamine, gabapentin, and clonidine have 
been reported as beneficial for localized pain which is neuropathic in nature [27, 28].
3.6.1 Opioid analgesics
Chronic pain management requires opioids, we need to consider pain diagnosis, 
risk/benefit of use of opioid in an individual, mental health and behavior. Opioid 
risk tool has been useful to note the risk and if it is high, consider goals and bound-
aries, verbal or written signed documents to encourage patient’s better behavior 
[18] (Table 1).
Goal setting—Chronic pain—opioids
Restful sleep at night
Brain activity sharp in the daytime
Affect, being better than neutral
Pain reduction by >30%
Improved activity and function
Physical, psychological rehabilitation
Plan for reduction of opioids—if pain improved
Table 1. 
Opioid use requires goal setting and needs to be shared with the patient, the first time and reminded on 
follow-up.
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Opioids use has been common, and morphine was considered as a “gold stan-
dard” for pain management few decades ago along with “no ceiling”. Initially, 
morphine was used for acute pain when the pain was excessive and Twycross, once 
he was able to establish physiological half-life of morphine, suggested every 4 h, 
and on the clock. In the early 1980s and before, opioids were short-acting oral pills, 
liquid, and injectable. Long acting opioids through formulation became available 
in the late 1980s and 1990s. Now tramadol, oxycodone, codeine, hydromorphone, 
morphine long acting oral medications along with transdermal fentanyl and 
buprenorphine are available [29] (Table 2).
Several animal and clinical studies have shown codeine, oxycodone, morphine, 
and fentanyl may have benefit relieving pain for short term but when used long term 
lead to glial and immune cells activation, leading to tolerance, allodynia, and hyper-
algesia [30, 31]. Hydromorphone long-term use has similar effect, opioid neurotoxic-
ity with twitching, myoclonus, unrestful night sleep, and minor agitation. Activation 
of glial cell is associated with N-methyl-D-Aspartate (NMDA) receptor and release of 
amino acid, glutamate which is neuroexcitatory [30, 31]. None of the above opioids 
have NMDA antagonism. Methadone and levorphanol have two racemic mixtures 
opioid with half-life 7–8 h and non-opioid, NMDA antagonist, norepinephrine, and 
serotonin re-uptake inhibition. Ketamine has NMDA antagonism but adverse effects 
in relation to tolerance and mental health issues are high [32] (Table 3).
3.6.2 Opioid use
For the use of opioids as analgesics we need to consider pharmacokinetics, active 
metabolites, half-life, and excretion. “Start low and go slow” has been the principle 
and in pain crisis either opioid toxicity or pain is not responding requires higher 
Boundary setting—high risk—opioids
Strict boundary setting is essential
Treatment agreements—(verbal/signed)
Urine drug testing (UDT)
Interval/contingency dispensing
Table 2. 
High risk in a patient with opioids or substance and opioid use disorder likely, consider boundary setting and 
improving behaviour.
What activates glia and immune cells?
Pro-inflammatory cytokines
Chemokines
ATP
Neuropeptides
Prostaglandins
Glutamate
Nitric oxide
Endogenous danger signals
Table 3. 
Long-term opioid use can activate glia and immune cells causing tolerance, allodynia, and hyperalgesia and 
considering how to approach pain management.
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doses. Opioid switch in such states and 20–30% reduction of equianalgesic opioid 
need to be considered. Breakthrough pain, if it occurs 10% of 24-h dose of the 
opioid is used as a dose and around half-life such dose is given [33].
The short-term use of opioids may be useful for acute pain, but the long-term 
use is associated with activation of glial and immune cells with neuroexcitatory 
chemicals along with tolerance and hyperalgesia [30, 31] (Figure 5).
Methadone is available as two racemic mixtures; R-methadone is an opioid with 
lower half-life and S-methadone is NMDA antagonist, Norepinephrine, and sero-
tonin re-uptake inhibitor. Methadone has been used as harm-reduction for opioid 
use disorder and being used as an analgesic. Rapid titration using German, Morley 
Makin, Kansas, and Edmonton method in the form of stepped approach to opioid 
switch is possible [34, 35].
Methadone is also used when neuropathic and nociplastic pain is associated with 
existing opioid toxicity; twitches, jerks (myoclonus) and neurotoxicity with confu-
sion and delirium. In such state, it is possible to use low dose twice or three times a 
day and ultra-low dose with slow titration is possible along with existing opioid or 
co-analgesics can be reduced and stopped gradually if benefit is noted [36]. Patients 
with mental health issues require higher dose and patients who are comfortable 
psychologically, pain relief and physical suffering require very low dose of metha-
done for cancer, acute or chronic kidney disease (Tables 4–6).
3.6.3 Adverse effects associated with the use of opioids
Nausea, minor hallucinations, and somnolence are common at the start of opioids, 
if the dose remains the same in a few days often such symptoms fade or require lower 
dose of opioid or therapeutic intervention for the symptom.
Glia and Immune cells release neuroexcitatory, pain enhancing substances
Arachidonic acid and prostaglandins
Excitatory amino acids (glutamate)
Pro-inflammatory cytokines/chemokines
Nerve growth factors
Reactive oxygen and nitrogen species
Table 4. 
Neuroexcitatory chemicals enhance pain and the present and future research has a value to improve pain and 
suffering.
Figure 5. 
Animal and clinical studies have shown Codeine, Oxycodone, Morphine, and Fentanyl when used long term, 
leads to neurotoxicity: Tolerance, allodynia and hyperalgesia and we need to consider better interventions to 
reduce pain and suffering.
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Dry mouth and constipation are common and require water sipping and laxa-
tives, respectively.
Respiratory depression can occur with high doses of opioids.
Reduction androgen/testosterone can occur due to long-term use of opioids.
Neurotoxicity can occur associated with infection, renal insufficiency, and other 
medications; consists of hallucinations, delirium, twitching, jerks (myoclonus) and 
seizures. Such symptoms require reducing existing opioid, opioid switch, or adjunct 
medications.
Methadone and other substrates with enzyme interactions can lead to serotonin 
syndrome and QT/QTc prolongation.
3.6.4 Use of assessment tools
• Brief pain inventory (BPI) [37].
• The DN4 questionnaire [38, 39].
• Edmonton symptom assessment system revised (ESAS-R) [40].
• Opioid risk tool (ORT) [18].
• Pain disability index (PDI) [41].
• Roland Morris scale [42].
Opioid pharmacokinetics and use as an analgesic
Opioid Half-Life Active metabolites Excretion Start dose
Codeine 3–4 hrs Morphine Renal 30 mg Q4h
Oxycodone 2–6 hrs Oxymorphone Renal 5 mg Q4h
Morphine 2–4 hrs M6G, M3G Renal 1 mg Q4h
Hydromorphone 2–4 hrs H6G, H3G Renal 1 mg Q4h
Fentanyl patch 17 hrs Norfentanyl Renal 12 mcg/h
Methadone 6–150 hrs None known Hepatic 1 mg? Q8h
Buprenorphine patch 37 hrs B3G, NorB3G Hepatic 5 mcg/h, Q7days
Opioid use as an analgesic, “start low and go slow” for pain management. Once pain is stable, same long acting 
opioid can be used to reduce tolerance. Medications Fentanyl patch, Methadone and Buprenorphine patch are long 
acting, and dose need to be adjusted, taking half-life into consideration.
Table 5. 
Opioid use as an analgesic and “start low and go slow” for pain management.
Cancer clinic internal protocol methadone—Calgary
1–7 days 7–14 days 14–21 days 21–28 days 28–35 days 35–42 days
1 mg daily 1 mg Q12h 1 mg Q8h 2 mg Q8h 3 mg q8h 5 mg Q8h
2.5 mg daily 2.5 mg Q12h 2.5 mg Q8h 5 mg Q8h 7.5 mg Q8h 10 mg Q8h
At the Tom Baker Cancer Centre, Pain Clinic in Calgary, Canada an Internal Protocol was applied to patients 
with opioids and pain has not improved. Evidence relating to neurotoxicity, tolerance, allodynia, and hyperalgesia 
methadone has been used at ultra-low dose and slow titration to relieve pain.
Table 6. 
Opioid use as an analgesic and “start low and go slow” for pain management.
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3.6.5 Malignant bowel obstruction (MBO)
Carcinomatosis can occur with cancer, intra-abdominal organs and results in 
bowel obstruction with pain and cramps. If it is localized surgery is helpful. If the 
obstruction can be seen by gastrointestinal endoscopy a stent can be inserted with 
pain and obstruction relief. However, if the obstruction on the bowel being multiple 
sites dexamethasone and somatostatin analogue is used subcutaneously. Initially 
injectable opioids are used for pain relief, and if obstruction is relived can reduce 
and stop opioids but somatostatin analogue may continue [43, 44].
4. Opioids, pain and substance use disorder
Chronic pain in patients with cancer, noncancer injury related, organ failure 
renal insufficiency, and trauma related individuals if they are at the end of life pain 
and have substance use disorder (SUD), we need to consider “comfort care” as goals 
and assist as best as we can.
However, similar patients engaged in survivorship, SUD need to be assessed and 
mental health/addiction services, need to be collaborated. Some of the patients with 
SUD or opioid use disorder (OUD) require Mu-agonist therapy using methadone or 
suboxone.
5. Potential future treatments for pain
We need to consider further research to improve care for individual patient. 
Chronic pain is considered as an illness with suffering. Several organizations have 
been working and care providers need to engage in raising questions and proceeding 
with research investigation.
Investigations and research in relation to genetics, non-opioids like; ion chan-
nels, alpha-2-agonists, glia, and immune cells along with non-pharmacological 
approach physical, psychological, social, spiritual rehabilitation and research in 
nutrition is worthwhile.
6. Conclusion
Palliative care consists of patients with illness in the early phase and advanced 
end of life care. Patient’s wishes, worries, goals of care, and shared decisions along 
with subjective symptom like pain need to be considered.
Chronic pain is an illness and remains as a subjective symptom for an individual. 
Biopsychosocial, spiritual, and medical approach can benefit patient, family, 
and community. As care providers we ought to be up to date, evidence supported 
approach to relieve suffering of patient and family. Animal experiments and human 
clinical research have given care providers knowledge, and application of pain 
management can be better.
Acute pain often heals within days to weeks, but when the pain persists from an 
injury for more than three months chronic pain is considered. Central excitatory 
chemicals in the central nervous system can increase pain expression. Such change 
allows anxiety, frustration, and mental health issues.
Interventions like interventional, psychological, physical, pharmacological and 
nutrition have a value to reduce the chronic pain illness, suffering and improve 
function in an individual.
Pain Management
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In the future, a2–Adrenergic agonists, ion-channel modifiers, and nanotechnol-
ogy using nanoparticles to transport pharmaceuticals to reduce adverse effects and 
improve efficiency have a value in pain management and being investigated.
Thus, consider individual patient despite common diagnosis, require self-man-
agement skills, and endure or improve symptoms using appropriate therapies.
Education of care providers, patients and families is important; avoid stigmatiz-
ing an individual with chronic pain, substance use disorder, poor quality of life and 
mental health issues.
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